what is an announcement bar



This study has opened in Australia for patients with advanced low or intermediate grade neuroendocrine tumours (NETs). These are uncommon tumours in the gastrointestinal tract which occur particularly in the pancreas or the midgut. Those from each site will be studied separately within the study. In Australia patients may be treated with PRRT, which involves giving a radioactive compound by vein which then targets onto the tumour cells. In the study, for the midgut NETs, they will compare giving PRRT alone with also giving tablet chemotherapy, which will be a combination of capecitabine and temozolomide (called CAPTEM for short). For the pancreatic NETs, the study will compare capecitabine/temozolomide chemotherapy alone with adding PRRT to it. At this stage New Zealand patients will not be able to participate, unless PRRT becomes available. So far, each of these treatments are used in some patients, but there has been very little evidence from trials evaluating them against each other, to help choose the best approach.